INTRODUCTION
Melanoma incidence is rising in the US and throughout the world. In the US, an estimated 76,250 people will be diagnosed with cutaneous melanoma in 2012 (1) and by 2015, the estimated lifetime risk of developing this disease in the US will be one in fifty (2, 3) . These estimates may underestimate the true incidence of melanoma due to the large number of patients treated in the outpatient setting. Physicians diagnosing new cases of melanoma in the outpatient setting are required to report to the State's cancer registry. However, a half of dermatologists are not aware of this obligation and therefore a large number of melanomas are not reported. Thus, US melanoma statistics markedly underestimate the true incidence of the disease (4).
Melanoma is most commonly diagnosed at a clinically localized stage when it is highly curable by surgical removal. However, not all patients present with localized disease. Moreover, determining the risk of metastasis in patients diagnosed with localized melanoma continues to pose a challenge to both clinicians and pathologists (5) . A combination of clinical and pathological features is used for predicting outcomes in patients with localized melanoma. The most important prognostic features include tumor thickness, ulceration, Clark level of invasion and mitotic rate (6) (7) (8) (9) . However, these prognostic factors are limited in their ability to reliably distinguish patients that will manifest regional lymph node metastasis or develop widely disseminated disease and hence are at high risk of dying from melanoma. Currently, the most important predictor of distant metastasis and survival in patients with melanoma is sentinel lymph node (SLN) metastasis (10) (11) (12) . However, SLN biopsy requires examination of multiple microscopic SLN sections (5) and carries risk including wound complications, mild to moderate degrees of lymphedema, thrombophlebitis and loss of range of motion (9, 13) .
There is therefore an urgent need to identify new predictive and prognostic biomarkers (5, 14) in order to improve prediction models and to target therapies to individual melanoma patients.
Angiogenesis, the development of new blood vessels, and lymphangiogenesis, the development of new lymphatic vessels or the activation of pre-existing vessels promote tumor growth and metastasis (15, 16) . These two related processes are governed by many of the same genes (17) (18) (19) and the expression of these genes or their protein products has been correlated with tumor stage, progression, metastasis and survival in melanoma (5, 14, (20) (21) (22) (23) (24) (25) (26) (27) . It is therefore plausible that genetic variations in components of these two pathways may contribute to inter-individual differences in melanoma progression and survival.
Although strong biological rationale exists for the involvement of angiogenesis and lymphangiogenesis in melanoma, few studies have examined the association between genetic variants in these pathways and melanoma progression and survival.
Suggestive findings have been reported in studies examining the association of MMP-9
SNPs with intransit metastasis (28) and tumorigenesis (29) , MMP-1 SNPs with progression and prognosis (30) , VEGF SNP with tumor growth (31), IL1β SNP with thinner invasive melanoma (32) , EGF functional SNP with tumorigenesis (23) , and IL10 SNP with advanced disease (33) . However, no study to date, has examined associations of SNPs in these pathways with metastasis to SLNs.
In this study, we examined the association between 238 SNPs in 26 angiogenesis and lymphangiogenesis genes and the risk of SLN metastasis and mortality using data from 552 patients referred to the Moffitt Cancer Center ( Tampa, FL) for SLN biopsy for purposes of melanoma staging. We sought to replicate the statistically significant results in an independent population of 1,115 melanoma patients who had been genotyped as part of a genome-wide association study at MD Anderson Cancer Center (Houston, TX). The likelihood ratio test in logistic regression was used to estimate associations between SNPs in angiogenesis genes and SLN metastasis. For evaluating SNPs associated with melanoma death, the competing risk regression (CRR) approach was applied. Survival time was determined as the number of months between date of SLN biopsy and date of death due to melanoma (primary event), death due to other causes, or last contact for censored observations. All models were adjusted for age at diagnosis and Breslow depth. Statistical tests were two-sided with an alpha level < 0.05 considered statistically significant. For each SNP, the minimum P-value over three genetic models (additive, dominant, and recessive models) was used to represent the best-fitting model. For multiple comparison adjustment, the false discovery rate (FDR) q-value (38) for each SNP was evaluated. CRR was performed using the cmprsk R package, and other statistical analyses were implemented with SAS 9.2 (SAS Institute, NC).
MATERIALS AND METHODS

Study patients and data collection
Genotyping and data quality control for MDACC samples Samples were collected from the University of Texas MD Anderson Cancer Center. DNA samples for the first-stage genome-wide association study were genotyped using the Illumina HumanOmni1-Quad_v1-0_B array and were called using pseudoautosomal SNPs were available for the final association analysis. Samples with >10% missing rate across all SNPs (n=41), with identity problem (n=11), expectedly (n=67) or unexpectedly (n=5) duplicated or related (n=15) identified using IBD coefficient in PLINK, or identified as outliers by PCA (n=39) were removed. Imputation of ungenotyped SNPs in the whole genome was performed through MACH using HapMap reference data with a denser set of markers. We were able to fill in the untyped markers in the study subjects by means of maximum likelihood estimation. After imputation, we had 2.65 million SNPs available for this analysis. The average posterior probability for the most likely genotype was 0.99.
Statistical analysis for MDACC set. Combined Meta-analysis A meta-analysis was performed in Stata (version 8.2) to combine results across the two studies when odds ratios were in the same direction and the P value for each study was less than 0.1. The Q test of heterogeneity was estimated to quantify the proportion of total variation due to heterogeneity across studies. No significant heterogeneity was observed between the studies (all P > 0.33). Combined ORs, 95% CIs, and P values were generated using inverse-variance weighting to calculate a fixedeffect model.
RESULTS
The mean ages at diagnosis of SLN positive subjects was non-significantly lower than those of SLN negative subjects in both data set (P=0.08, Table 1 ). The distributions of males and females and tumor site did not differ between SLN positive and negative subjects ( (Table 3) .
Carriers of a minor allele at these SNPs, except for PDGFD rs17423306 and LZTS1 rs2645385, were associated with an increased risk of melanoma specific mortality.
GWAS data from MDACC set replicated the result only for rs2220377 in PDGFD (Table 3 ) with a FDR q-value=0.37. Furthermore, we performed a meta-analysis that combined results across the two studies for four SNPs [including rs2220377] with odds ratios in the same direction and P-value < 0.1 in each study. We identified three additional SNPs in the meta-analysis that were significantly associated with SLN metastasis (EGFR rs723526 and TLR3 rs3775292) and melanoma specific death (TLR3 rs7668666) (Figure 1 with melanoma. To our knowledge, this is the first study to comprehensively examine genetic variation in the angiogenesis and lymphangiogenesis pathways in relation to melanoma progression. We found suggestive evidence that genetic variants of PDGFD, EGFR, and TLR3 may influence the risk of SLN metastasis and/or death with replication provided for several of the implicated SNPs in a genome-wide scan and meta-analysis.
The mechanism of progression of malignant melanoma cells is still poorly understood.
However, it is known that angiogenesis and lymphangiogenesis have been investigated primarily on progression of cancers (15, 16) and play an important role in the progression of melanoma. Previous studies reported that new blood and lymphatic vessels promote the metastatic spread of tumors and correlated with tumor stage, progression, metastasis and survival in melanoma (5, 14, (20) (21) (22) (23) (24) (25) (26) (27) . Therefore, angiogenesis and lymphangiogenesis were suggested as a prognostic indicator for risk for progression of melanoma. A few of the best characterized genes for these pathways are PDGF, EGFR and TLR3.
Platelet-derived growth factors (PDGFs) are important in proliferation, apoptosis, transformation, migration, invasion, angiogenesis, and metastasis (40) . Among four PDGF family members, PDGF-D is involved in inflammation and angiogenesis (41, 42) .
Studies have shown that PDGFD is an inducer of transformation in vitro and promoter of tumorigenesis in vivo (43) and that PDGFD stimulates tumor vessel pericyte abundance and enhances tumor growth rate in melanoma (44) . No published studies have examined the significance of genetic variation of PDGFD in melanoma. In the current data, a common SNP (rs2220377) in the intron region of the PDGFD gene was associated with an 80% increase in the risk of melanoma-specific death. These results 
were replicated in the independent MDACC validation set. While the intronic rs2220377 variant itself is unlikely to have functional impact, the variant may be in linkage disequilibrium with another SNP that enhances function of PDGFD, creating a milieu favorable to growth and metastasis of tumor cells.
TLRs are involved in acquired immunity and the detection of pathogens including cancer debris (45) (46) . SNPs in TLR2, TLR3 and TLR4 showed statistically significant differences in the distribution of inferred haplotypes between cases and controls. However, no individual SNP was significantly associated with disease susceptibility. TLR3 is abnormally upregulated on cells isolated from melanoma biopsies and its activation induces melanoma cell migration both in vivo and in vitro (47) . In the present study, one SNP in the intron region of TLR3 (rs3775292) was significantly associated with SLN metastasis and another SNP (rs7668666) with melanoma specific death, both statistically significant in a meta-analysis combining Moffitt and the MDACC series. These data were supported by recent studies demonstrating over-expression of cytoplasmic EGFR in melanoma as compared to benign nevi (49) and higher expression levels in melanoma patients with SLN positive than patients with SLN negative tumors (50) . In the present study, a common variant in the promoter region of the EGFR gene (rs723526) was found to be associated with a significant 2.3-fold increase in risk of SLN metastasis in the meta-analysis.
Associations in several other angiogenesis and lymphangiogeneis genes, including FGFR4, FLT1, and PIK3CA were identified in Moffitt data consistent with findings of several previous studies (25, 51, 52) . However, these associations were not validated in the MDACC series indicating the need for further studies to determine the impact of these genes on melanoma outcome.
The present study benefits from several strengths including a relatively large number of melanoma cases, the selection of genes based on strong biological rationale, pathologically confirmed cases, and the availability of SLN biopsy results, as well as availability of clinical and survival data for all cases. Furthermore, we attempted to replicate our results in a recent GWAS of melanoma. Our meta-analytic approach, using a liberal p-value less than 0.1 for selecting and then pooling data on SNPs in the discovery and replication datasets, may be exploratory. Therefore, the identified two SNPs (TLR3 rs3775292 and TLR3 rs7668666; Figure 1 ) are good candidates that need to be confirmed in future studies. Although we evaluated a comprehensive list of genes in angiogenesis and lymphangiogenesis pathways, our list was not complete and other genes and SNPs not evaluated in the present study could potentially contribute to SLN metastasis or survival in melanoma. across the two studies when the estimates were in the same direction and the P value for each study was less than 0.1. The Q test of heterogeneity was estimated to quantify the proportion of total variation due to heterogeneity across studies. No significant heterogeneity was observed between the studies (all P > 0.33). Combined ORs, 95%
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